Table 1 Current and future technology for staging primary cervical cancers. MRI magnetic resonance imaging, ¹⁸ FDG ¹⁸F-fluorodeoxyglucose, PET positron emission tomography, CT computed tomography, SNB sentinel node biopsy, ⁶⁰ Cu-ATSM ⁶⁰Cu-diacetyl-bis (N⁴-metylthiosemicarbazone), ¹⁸ F-FMISO ¹⁸F-fluoromisonidazole, USPIO MRI ultra small paramagnetic iron oxide-enhanced magnetic resonance imaging

From: Whole-body ¹⁸FDG PET plus pelvic MRI in the pre-treatment assessment of cervical cancers: an alternative to the FIGO clinical staging